Abstracts tagged "pain management"

Abstract Number: 146 • 2020 Pediatric Rheumatology Symposium
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Saumya Joshi¹, Yujuan Zhang ¹, Lori Lyn Price ², Trevor Davis ³ and Raveendhara Bannuru ¹, ¹Tufts Medical Center, Boston, Massachusetts, ²Boston, Massachusetts, ³Norwell, Massachusetts
Background/Purpose: Amplified Musculoskeletal Pain Syndrome (AMPS), a chronic pain syndrome with excessive musculoskeletal pain without a primary organic etiology, has a high prevalence in adolescents.…
Abstract Number: 827 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
Gregory Sullivan¹, R. Michael Gendreau ², Judith Gendreau ³, Ashild Peters ⁴, Perry Peters ⁵ and Seth Lederman ⁶, ¹Tonix Pharmaceuticals Inc., New York, ²Gendreau Consulting, Poway, CA, ³Tonix Pharmaceuticals Inc, Poway, CA, ⁴Tonix Pharmaceuticals Inc., San Diego, CA, ⁵Tonix Pharmaceuticals Inc, San Diego, CA, ⁶Tonix Pharmaceuticals Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, unrefreshing sleep, fatigue, and cognitive complaints. TNX-102 SL* is a sublingual (SL) formulation of cyclobenzaprine (CBP)…
Abstract Number: 2049 • 2019 ACR/ARP Annual Meeting
National Estimates of Pain Medication Use in Patients with Osteoarthritis
Mohammed Saeed¹, ¹Capital Health, Trenton, NJ
Background/Purpose: The epidemiology of pain medication use among patients with osteoarthritis is not well explored. Chronic kidney disease (CKD) modifies choice of analgesics. The aim…
Abstract Number: 2244 • 2019 ACR/ARP Annual Meeting
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Thomas Schnitzer¹, Rebecca Robinson ², Lars Viktrup ², Joseph Cappelleri ³, Andrew Bushmakin ³, Leslie Tive ⁴, Jennifer Mellor ⁵, Nathan Williams ⁵, Pavlina Hubanova ⁵ and James Jackson ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Eli Lilly and Company, Indianapolis, IN, ³Pfizer Inc, Groton, CT, ⁴Pfizer, Inc, New york, NY, ⁵Adelphi Real World, Bollington, England, United Kingdom
Background/Purpose: To describe patterns of care and physician satisfaction with prescribed treatments for osteoarthritis (OA).Methods: Data were collected from February-May 2017 using US Adelphi Disease…
Abstract Number: 2343 • 2018 ACR/ARHP Annual Meeting
Exploring Decision Making Needs about Pain Management Among Adolescents with Juvenile Idiopathic Arthritis and Their Families: Preliminary Results from Interviews
Karine Toupin-April¹, Jennifer N. Stinson², Adam Huber^3,4, Ciarán M. Duffy⁵, Isabelle Gaboury⁶, Esi Morgan^7,8, Lucie Brosseau⁹, William Brinkman^7,8, Linda Li¹⁰, Tania El Hindi¹¹, Aditi Sivakumar¹¹, Marg Bisch¹², Janice Cohen¹³, Elizabeth Stringer¹⁴, France Légaré¹⁵, Laurie Proulx¹⁶, Paul R. Fortin¹⁷ and Peter Tugwell¹⁸, ¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ³IWK Health Centre, Halifax, NS, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶Universite de Sherbrooke, Sherbrooke, ON, Canada, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸University of Cincinnati, Cincinnati, OH, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰Arthritis Research Canada, Richmond, BC, Canada, ¹¹Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ¹³Children's Hospital of Eastern Ontario Research Institute, ottawa, ON, Canada, ¹⁴Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹⁵Laval University, Montreal, QC, Canada, ¹⁶Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ¹⁷Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁸Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada
Background/Purpose: Adolescents with juvenile idiopathic arthritis (JIA), one of the most common causes of chronic musculoskeletal pain among youth, face many difficult decisions. However, we…
Abstract Number: 2940 • 2018 ACR/ARHP Annual Meeting
Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic
Maggie Wimmer, Robyn Wiesel, Berenice Adams, Mikhaila Goldman, Titilayo Ologhobo, Yu Sun, Mavis Seehaus, Sandra Goldsmith and Laura Robbins, Hospital for Special Surgery, New York, NY
Background/Purpose: In 2018, according to the National Institute of Health, opioid misuse and addiction is a major public health issue. Approximately 70% of individuals who…
Abstract Number: 1974 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Xiao Zhang¹, Huji Xu², Zhiyi Zhang³, Yang Li⁴, Lynne Pauer⁵, Shanmei Liao⁶, Gaiping Xu⁷ and Fengchun Zhang⁸, ¹Guangdong General Hospital, Guangdong, China, Guangdong, China, ²Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ³The First Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁴The Second Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁵Pfizer, Groton, CT, USA, Groton, CT, ⁶Pfizer (China) Statistics Department, Global Innovative Pharma Business, Shanghai, China, Shanghai, China, ⁷Pfizer (China) Clinical Development, Global Innovative Pharma Business, Beijing, China, Beijing, China, ⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Global trial data demonstrate the efficacy of pregabalin for the treatment of pain associated with fibromyalgia (FM), but there are currently no approved medical…
Abstract Number: 2220 • 2017 ACR/ARHP Annual Meeting
Neuropathic-like Pain Affects the Tender Joint Count and Health-Related Quality of Life in Patients with Rheumatoid Arthritis
Kentaro Noda¹, Miku Tajima², Yosuke Oto³, Kazuhiro Otani³, Yoshiga Masayuki³, Haruyasu Ito¹, Ken Yoshida¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medecine, Jikei University School of Medicine, Tokyo, Japan, ³Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Pain in rheumatoid arthritis (RA) has been thought to be due to nociceptive pain, but it was reported recently to include a mechanism associated…
Abstract Number: 2226 • 2017 ACR/ARHP Annual Meeting
Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
James Campbell¹, Randall Stevens¹, Ira Gottlieb², Kimberly Guedes¹, Robin Burges¹, Margaret Kelly³ and Peter Hanson¹, ¹Centrexion Therapeutics, Boston, MA, ²Chesapeake Research Group, Pasadena, MD, ³Edirutop, Christiansburg, VA
Background/Purpose: Morton’s neuroma (MN) is a painful condition of the third intermetatarsal space caused by distal common digital nerve compression. CNTX-4975 is a highly purified,…
Abstract Number: 95 • 2017 Pediatric Rheumatology Symposium
Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment
Jacqueline Warner¹, Erin Moorman¹, Natoshia Cunningham², Kasha Wiley³, Allen Watts³, Susmita Kashikar-Zuck⁴ and Hermine Brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: cSLE can result in considerable decrements in health-related quality of life (HRQOL) for young patients. Youth with cSLE experience a myriad of symptoms, including…
Abstract Number: 52 • 2016 ACR/ARHP Annual Meeting
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…
Abstract Number: 2403 • 2016 ACR/ARHP Annual Meeting
Sleep Disruption in Children with Chronic Pain
Cara Hoffart¹, Santana Fortney² and Dustin Wallace³, ¹Rheumatology and Pain Management, Children's Mercy Hospital, Kansas City, MO, ²Children's Mercy Hospital, Kansas City, MO, ³Integrative Pain Management and Developmental and Behavioral, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Sleep disorders and fatigue are common in children with chronic pain syndromes, and contributes to psychosocial dysfunction, healthcare utilization, and school absences. We hypothesize…
Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting
Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Ara H. Dikranian¹, Rubaiya Mallay², Mike Marshall³, Megan Francis-Sedlak³ and Robert J. Holt^4,5, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, ⁵College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL
Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
Abstract Number: 378 • 2016 ACR/ARHP Annual Meeting
Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series
Annalouise O'Connor¹, Sara Le Brun-Blashka², Kirti Salunkhe², Jyh-Lurn Chang² and John Troup², ¹R&D, Metagenics, Inc., Gig Harbor, WA, ²Metagenics, Inc., Gig Harbor, WA
Background/Purpose: The inflammatory response has an initiation phase and a resolution phase. Ideally, inflammation leads to complete resolution that enables tissue healing and a return…
Abstract Number: 439 • 2016 ACR/ARHP Annual Meeting
Temple University Hospital Rheumatology Narcotic Contract
Alexis Zavitsanos¹, King Goh², Shikha Rathi³, Alice Livshits³ and Irene Tan³, ¹Rheumatology, Temple University Hospital, Philadelphia, PA, ²Rheumatology, Temple University, Philadelphia, PA, ³Temple University Hospital, Philadelphia, PA
Background/Purpose: The use of opioids in treating chronic pain can be difficult and is a common problem across multiple specialties, including rheumatology. Opioid contracts have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].